Milan, Italy – Tensive S.r.l, a clinical-stage company specializing in advanced biomaterials, has revealed promising developments regarding its REGENERATM bioresorbable scaffolds. On March 4, 2026, independent researchers from the University of Pisa and the AOUP Breast Center presented their findings at the European Congress of Radiology (ECR 2026) held in Vienna, Austria. The focus of their study was on the potential applications of these scaffolds in breast reconstruction and tissue marking.
The research highlighted the innovative properties of the REGENERATM scaffolds, which are designed to provide structural support during the healing process. Unlike traditional materials, these bioresorbable scaffolds gradually dissolve in the body, reducing the need for additional surgeries to remove implants. The study’s authors emphasized that this technology could significantly improve patient outcomes by minimizing complications associated with conventional reconstruction methods.
In a detailed presentation, the investigators shared data demonstrating the scaffolds’ effectiveness in promoting tissue regeneration and integration within the surrounding biological structures. The results indicate that patients experienced fewer adverse effects, paving the way for broader adoption in clinical practices.
The significance of this study at ECR 2026 cannot be overstated. As the medical community continues to explore less invasive solutions for breast reconstruction, Tensive S.r.l stands at the forefront of this evolution. The company is optimistic that the positive findings will encourage further research and eventual regulatory approval for widespread use.
Tensive S.r.l has positioned itself as a leader in biomaterials innovation, with a commitment to enhancing surgical outcomes through advanced technologies. The ongoing collaboration with esteemed institutions like the University of Pisa underscores the company’s dedication to rigorous scientific investigation and validation of its products.
As interest in bioresorbable materials grows, Tensive S.r.l is actively engaging with healthcare professionals and researchers to facilitate discussions on best practices and implementation strategies. The company aims to ensure that the implications of this study are fully realized in clinical settings, ultimately benefitting patients seeking reconstructive options.
The ECR 2026 presentation marked a significant milestone for Tensive S.r.l, showcasing the potential of its REGENERATM scaffolds to transform breast reconstruction procedures. With further studies on the horizon, the company is poised to make substantial contributions to the field of advanced biomaterials and patient care.
